Thiotepa-associated cardiomyopathy during blood or marrow transplantation: Association with the female sex and cardiac risk factors

Biology of Blood and Marrow Transplantation

Volumn 5, Issue 5, 1999, Pages 322-327

  Alidina, Amyn ^a   Lawrence, David ^a   Ford, Laurie Ann ^a   Baer, Maria R ^a   Bambach, Barbara ^a   Bernstein, Steven H ^a   Czuczman, Myron S ^a   Slack, James L ^a   Spangenthal, Edward ^a   Wetzler, Meir ^a   Barcos, Maurice P ^a   Proulx, Gary M ^a   Anderson, Barbara ^a   McCarthy Jr , Philip L ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Blood and marrow transplantation; Conditioning regimen; Congestive heart failure; Left ventricular ejection fraction; Thiotepa

Indexed keywords

ALKYLATING AGENT; CYCLOPHOSPHAMIDE; THIOTEPA;

ADULT; ANIMAL; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHY; CHEMICALLY INDUCED DISORDER; CONGESTIVE HEART FAILURE; FEMALE; HEART STROKE VOLUME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CARDIOMYOPATHIES; CYCLOPHOSPHAMIDE; FEMALE; HEART FAILURE, CONGESTIVE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; THIOTEPA;

EID: 0032613917     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(99)70008-X     Document Type: Article

References (42)

1. Fields KK, Elfenbein GJ, Perkins JB, Hiemenz JW, Janssen WE, Zorsky PE, Ballester OF, Kronish LE, Foody MC: Two novel high-dose treatment regimens for metastatic breast cancer-ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcome and toxicities. Semin Oncol 20:59, 1993.
2. Holland HK, Dix SP, Geller RB, Devine SM, Heffner LT, Connaghan DG, Hillyer CD, Hughes LL, Miller RL, Moore MR, Winton EF, Wingard JR: Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 14:1156, 1996.
3. Fontelonga A, Kelly AJ, MacKintosh FR, Hall S, Monroe P, Wilson GS, Shaft D, Ruthven A, Ascensao JL: A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma. Bone Marrow Transplant 19:983, 1997.
4. Kamani N, August CS, Bunin N, Leabey A, Bayever E, Goldwein J, Zusman J, Evans AE, Angio GD: A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma. Bone Marrow Transplant 17:911, 1996.
5. Finlay JL, Goldman S, Wong MC, Cairo M, Garvin J, August C, Cohen BH, Stanley P, Zimmerman RA, Bostrom B, Geyer JR, Harris RE, Sanders J, Yates AJ, Boyett JM, Packer RJ: Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. J Clin Oncol 14:2495, 1996.
6. Bouffet E, Mottolese C, Jouvet A, Philip I, Frappaz D, Carrie C, Brunat-Mentigny M: Etoposide and thiotepa followed by ABMT (autologous bone marrow transplantation) in children and young adults with high-grade gliomas. Eur J Cancer 33:91, 1997.
7. Rodenbuis S, van der Wall E, ten Bokkel Huinink WW, Schornagel JH, Richel DJ, Vlasveld LT: Pilot study of a high-dose carboplatin-based salvage strategy for relapsing or refractory germ cell cancer. Cancer Invest 13:355, 1995.
8. Wolff SN, Herzig RH, Fay JW, LeMaistre CF, Frei-Labr D, Lowder J, Bolwell B, Giannone L, Herzig GP: High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Marrow Transplantation Group. J Clin Oncol 7:245, 1989.
9. Przepiorka D, Ippoliti C, Giralt S, van Besien K, Mehra R, Deisseroth AB, Anderson B, Luna M, Cork A, Lee M, Estey E, Andreeff M, Champlin R: A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic marrow transplantation. Bone Marrow Transplant 14:449, 1994.
10. Bacigalupo A, Van Lint MT, Valbonesi M, Lercari G, Carlier P, Lamperelli T, Gualandi F, Occhini D, Bregante S, Valeriani A, Piaggio G, Pitto A, Benvenuto F, Figari O, De Stefano G, Caimo A, Sessarego M: Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. Blood 88:353, 1996.
11. Dimopoulos MA, Alexanian R, Przepiorka D, Hester J, Andersson B, Giralt S, Mehra R, van Besien K, Delasalle KB, Reading C, Deisseroth AB, Champlin RE: Thiotepa, busulfan, and cyclophosphamide: a new preparative regimen for autologous marrow or blood stern cell transplantation in high-risk multiple myeloma. Blood 82:2324, 1993.
12. Antman K, Eder JP, Elias A, Ayash L, Shea TC, Weissman L, Critchlows J, Schryber SM, Begg C, Teicher BA, Schnipper LE, Freii E III: High-dose thiotepa alone and in combination regimens with bone marrow support. Semin Oncol 17:33, 1990.
13. Wolff SN, Herzig RH, Fay JW, LeMaistre CF, Brown RA, Frei-Lahr D, Stranjord S, Giannone L, Coccia P, Weick JL, Rothman SA, Krupp KR, Lowder J, Bolwell B, Herzig GP: High-dose N,N′,N″ triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol 17:2, 1990.
14. Schiffman K, Buckner CD, Maziarz R, Maloney DG, Appelbaum FR, Press O, Gooley T, Holmberg L, Lilleby K, Clift R, Zuckerman N, Klarnet J, Weaver C, Chauncey T, Bensinger WI: High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease. Biol Blood Marrow Transplant 3:261, 1997.
15. Appelbaum F, Strauchen JA, Graw RG Jr, Savage DD, Kent KM, Ferrans VJ, Herzig GP: Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1:58, 1976.
16. Steinberz LJ, Steinherz PG, Mangiacasale D, O'Reilly R, Allen J, Sorell M, Miller DR: Cardiac changes with cyclophosphamide. Med Pediatr Oncol 9:417, 1981.
17. Goldberg MA, Antin JH, Guinan EC, Rappeport JM: Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 68:1114, 1986.
18. Bearman SI, Petersan FB, Schar RA, Denny JD, Fisher LD, Appelbaum FR, Buckner CD: Radionuclide ejection fractions in the evaluation of patients being considered for bone marrow transplantation: risk for cardiac toxicity. Bone Marrow Transplant 5:173, 1990.
19. Brown RA, Wolff SN, Fay JW, Pineiro L, Collins RH Jr, Lynch JP, Stevens D, Greer J, Herzig RH, Herzig GP: High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant Group. Blood 85:1391, 1995.
20. Tutschka PJ, Copelan EA, Klein JP: Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 70:1382, 1987.
21. Peters WP, Ross M, Vredenburgb JJ, Meisenberg B, Marks LB, Winer E, Kurztberg J, Bast RC Jr, Jones R, Shpall E, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132, 1993.
22. Jagannath S, Armitage JO, Dicke KA, Tucker SL, Velasquez WS, Smith K, Vaughan WP, Kessinger A, Horwitz LJ, Hagemeister FB, McLaugblin P, Cabanillas F, Spitzer G: Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 7:179, 1989.
23. Jagannath S, Vesole DH, Glenn L, Crovley J, Barlogie B: Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 80:1666, 1992.
24. Buckner CD, Rudolph RH, Fefer A, Clift RA, Efstein RB, Funk DD, Neiman PE, Slichter SJ, Storb R, Thomas ED: High-dose cyclophosphamide therapy for malignant disease. Cancer 29:357, 1972.
25. Corringham R, Gilmore M, Prentice HG, Boesen E: High-dose melphalan with autologous bone marrow transplant. Treatment of poor prognosis tumors. Cancer 52:1783, 1983.
26. Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SI, Peterson FB, Fisher LD, Anasetti C, Beatty P, Bensinger WI, Doney K, Hill RS, McDonald GB, Martin P, Meyers J, Sanders J, Singer J, Stewart P, Sullivan KM, Witherspoon R, Storb R, Hansen JA, Thomas ED: Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 77:1660, 1991.
27. Gluckman E, Auerbach AD, Horowitz MM, Sobocinski KA, Ash RC, Bortin MM, Butturini A, Camitta BM, Champlin RE, Friedrich W, Good RA, Gordon-Smith EC, Harris RE, Klein JP, Ortega JJ, Pasquini R, Ramsay NK, Speck B, Vowels MR, Zhang MJ, Gale RP: Bone marrow transplantation for Fanconi anemia. Blood 86:2856, 1995.
28. Mulder PO, de Vries EG, Koops HS, Splinter T, Maas A, van der Geest S, Mulder NH, Sleijfer DT: Chemotherapy with maximally tolerable doses of VP 16-213 and cyclophosphamide followed by autologous bone marrow transplantation for the treatment of relapsed or refractory germ cell tumors. Eur J Cancer Clin Oncol 24(4):675, 1988.
29. Blume KG, Forman SJ, O'Donnell MR, Doroshow JH, Krance RA, Nademanee AP, Snyder DS, Schmidt GM, Fahey JL, Metter GE, Hill LR, Findley DO, Sniecinski IJ: Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 69:1015, 1987.
30. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C, Appelbaum FR, Bowden RA, Deeg HJ, Doney K, Martin PJ, Sullivan KM, Sanders J, Witherspoon RP: Acute graft-vs.-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 80:1838, 1992.
31. Shepherd JD, Shore TB, Reece DE, Barnett MJ, Klingemann HG, Buskard NA, Phillips GL: Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease. Bone Marrow Transplant 3:553, 1988.
32. Alam A, Baer MR, Bernstein S, Bernstein Z, Christiansen N, Czuczman M, Schriber J, Slack J, Tezcan H, Wetzler M, Cooper M, Milk B, Ford L, Herzig G, McCarthy P: Phase II clinical trial of OKT3 for acute graft-vs.-host disease (GVHD) prophylaxis in allogeneic bone marrow transplantation (alloBMT). Blood 90 (Suppl. 1):102a, 1997.
33. Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O'Donnell MR, Parker PM, Smith EP, Snyder DS, Stein AS, Wong RM, Blume KG, Forman SJ: Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis for acute graft-vs.-host disease. N Engl J Med 329:1225, 1993.
34. Bearman SI, Appelbaum FR, Buckner CD, Peterson FB, Fisher LD, Clift RA: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562, 1988.
35. Dindogur A, Barcos MP, Henderson ES, Wallace HJ Jr: Electrocardiographic changes following adriamycin treatment. Med Pediatr Oncol 5:65, 1978.
36. Benoff LJ, Schweitzer P: Radiation therapy-induced cardiac injury. Am Heart J 129:1193, 1995.
37. Shan K, Lincoff AM, Young JB: Anthracycline-induced cardiomyopathy. Ann Intern Med 125:47, 1996.
38. Hagglund H, Remberger M, Klaesson S, Lonnqvist B, Ljungman P, Ringden O: Norethisterone treatment, a major risk-factor for venoocclusive disease in the liver after allogeneic bone marrow transplantation. Blood 92:4568, 1998.
39. Radich JP, Sanders JE, Buckner CD, Martin PJ, Peterson FB, Bensinger W, McDonald GB, Mori M, Schoch G, Hansen JA: Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens. J Clin Oncol 11:304, 1993.
40. Pannuti F, Bartoni F: Histopathological study of the heart-damaging effects of thiotepa on chick embryo "in situ." Quad Sclavo Diagn 8:669, 1972.
41. Giralt S, Estty E, Albitar M, van Besien K, Rondon G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harvesting graft-vs.-leukemia without myeloablative therapy. Blood 89:453, 1997.
42. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756, 1998.